Results 211 to 220 of about 24,071 (258)

Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

open access: yesAdvanced Science, EarlyView.
There is no drug targeting the NLRP3 inflammasome that has been approved for use in clinical settings. Ciclopirox olamine (CPX), an antifungal agent approved by the US Food and Drug Administration (FDA), is identified as a specific and potent NLRP3 inflammasome inhibitor. CPX targets the NACHT domain of NLRP3 at Y381 to impair NLRP3 oligomerization and
Xinyu Xia   +7 more
wiley   +1 more source

A method to identify prescription drug targets for health technology reassessment. [PDF]

open access: yesInt J Technol Assess Health Care
Hofmeister M   +4 more
europepmc   +1 more source

Assessment of High-Volume Antibiotic and Opioid Prescribing by Medicare Part D Prescribers-United States, 2021. [PDF]

open access: yesPublic Health Rep
Vazquez Deida AA   +6 more
europepmc   +1 more source

Pharmacist prescribers.

open access: yesJournal of primary health care, 2010
Wheeler, Amanda   +6 more
openaire   +2 more sources

Prevalence and predictors of prescribing errors in a primary care setting in Ghana. [PDF]

open access: yesTher Adv Drug Saf
Djochie RDA   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy